通过比较分子动力学方法调整levansucrase产品大小
Zhiwei Li1, Tong Bao1, Kaiwen Chen1
1College of Food and Biological Engineering, Hefei University of Technology, Hefei, China.
Enzyme and microbial technology
|December 25, 2024
概括
研究人员修改了levansucrase酶以控制levans分子量,这是食品添加剂应用中的关键因素. 这项研究确定了关键的酶循环,并设计了具有不同水平重量的突变物.
科学领域:
- 酶学 是一种酶学.
- 生物化学 生物化学
- 食品科学 食品科学 食品科学
背景情况:
- 莱万是一种多糖,是一种多用途的食品添加剂.
- 莱文的分子量显著影响其功能性质和应用.
- 来自不同微生物来源的Levansucrase酶,例如Bacillus subtilis (Bs-SacB) 和Priestia megaterium (Pm-SacB),产生具有不同分子重量的Levans.
研究的目的:
- 为了研究由Bs-SacB和Pm-SacB产生的高分子重量差异的分子基础.
- 为了在levansucrase酶中识别特定的区域,负责控制levans分子量.
- 为了设计具有改变Levon分子量配置的Levansucrase变体.
主要方法:
- 对Bs-SacB和Pm-SacB.的活性位点循环进行比较分析.
- 确定影响分子重量升高的关键环 (Loop3和Loop4).
- 用于酶工程的突变能量分析和非同源替代的应用.
- 突变酶及其激发产品分子重量的表征.
主要成果:
- 确定了Loop3和Loop4作为调节Bs-SacB.B.产生的Levans分子重量的关键决定因素.
- 在Loop3和Loop4中发生的工程突变导致了突变的Levansucrases,产生了具有不同分子重量的Levans (例如,F182Y在3698Da,CYTI在3093Da,3-Pbl在2776Da,4-Bml在1845Da,F182K在1571Da).
- 这项研究展示了一种新的比较分子动力学方法,用于控制酶产品的分子量.
结论:
- 在levansucrase酶中的特定循环极大地影响产生的levans的分子量.
- 向这些循环的酶工程策略可以精确地控制分子重量.
- 这项研究提供了一种有价值的方法,用于为食品科学和生物技术中的特定应用量身定制levansucrase活动.
相关概念视频
01:13Induced-fit Model
Most chemical reactions in cells require enzymes—biological catalysts that speed up the reaction without being consumed or permanently changed. They reduce the activation energy needed to convert the reactants into products. Enzymes are proteins, that usually work by binding to a substrate—a reactant molecule that they act upon.
Enzymes exhibit substrate specificity, meaning that they can only bind to certain substrates. This is mainly determined by the shape and chemical characteristics of...
Enzymes exhibit substrate specificity, meaning that they can only bind to certain substrates. This is mainly determined by the shape and chemical characteristics of...
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...